Jump to content
IGNORED

Covid-19: Razvoj vakcine, imunitet i primena medikamenata


beyoncé

Recommended Posts

Sad krene kuknjava "ne damo decu". Pregledao sam bar jedno 1500 adolescenata u posl dva meseca, mozda je ukupno 6 vakcinisano... tragicno

 

In other news, pfizer razvija mRNA vakcinu protiv citomegalovirusa

  • +1 1
Link to comment

Što se ove pandemije tiče, izgleda da jesu. Pokušaće doduše da naprave univerzalno rešenje za sve koronaviruse.

 

Quote

 

By the time the researchers published their findings however, several treatments had become available, including antiviral medications, antibody cocktails and vaccines. Prompted by these global advances, the team has shifted focus from COVID-19 to trying to create compounds that target all coronaviruses, including SARS and MERS, in a bid to design a universal therapeutics as a safeguard against future pandemics.

To this end, Kim has partnered up with a Boston biotech company Decoy Therapeutics to commercialize his research.

 

https://www.utoronto.ca/news/u-t-researchers-create-mirror-image-peptides-can-neutralize-sars-cov-2

Link to comment
Quote

Supercharging New Viral Variants: The Dangers Of Molnupiravir (Part 1)

As much as people are justifiably excited about the prospect for orally available drugs that can prevent and treat Covid-19, I believe the FDA needs to tread very carefully with molnupiravir, the antiviral currently before them for approval. My misgivings are founded on two key concerns. The first is the drug’s potential mutagenicity, and the possibility that its use could lead to birth defects or cancerous tumors. The second is a danger that is far greater and potentially far deadlier: the drug’s potential to supercharge SARS-CoV-2 mutations and unleash a more virulent variant upon the world. 

 

Link to comment

Uf, posle čitanja ona dva Haseltineova članka, meni ovo deluje mnogo opasno - ajd što mehanizam delovanja može da ošteti i zdravu DNK, nego što  nezavršena kutija leka može da pospeši mutacije, a pola ljudi koje znam batali antibiotike čim im je malo bolje, nema šanse da će svi biti disciplinovani s ovim...

 

Opet, onaj komentar na Blicu je u sridu, "Konačno za one koji se plaše bocke ali vole da gutaju sve i svašta"...

  • +1 2
Link to comment
Quote

PFIZER’S NOVEL COVID-19 ORAL ANTIVIRAL TREATMENT CANDIDATE REDUCED RISK OF HOSPITALIZATION OR DEATH BY 89% IN INTERIM ANALYSIS OF PHASE 2/3 EPIC-HR STUDY

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. The scheduled interim analysis showed an 89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset (primary endpoint); 0.8% of patients who received PAXLOVID™ were hospitalized through Day 28 following randomization (3/389 hospitalized with no deaths), compared to 7.0% of patients who received placebo and were hospitalized or died (27/385 hospitalized with 7 subsequent deaths). The statistical significance of these results was high (p<0.0001). Similar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset; 1.0% of patients who received PAXLOVID™ were hospitalized through Day 28 following randomization (6/607 hospitalized, with no deaths), compared to 6.7% of patients who received a placebo (41/612 hospitalized with 10 subsequent deaths), with high statistical significance (p<0.0001). In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID™ as compared to 10 (1.6%) deaths in patients who received placebo.

https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate

Edited by vememah
  • +1 4
Link to comment

Podsećanja radi, Merckov molnupiravir, tj. sada pod komercijalnim nazivom Lagevrio imao je osetnu manju efikasnost protiv hospitalizacije - nekih 50%, ali takođe niko od onih koji su ga primili nije umro.

 

Quote

At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo-treated patients (53/377); p=0.0012. Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo.

https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/

Edited by vememah
Link to comment
Quote

The Pfizer drug [Paxlovid], known as a protease inhibitor, is designed to block an enzyme the virus needs in order to multiply. When taken alongside a low dose of another antiviral pill called ritonavir, it stays in the body for longer.

Three pills are taken twice a day for five days.

The combination treatment, which is still experimental because trials haven't finished, works slightly differently to the Merck pill which introduces errors into the genetic code of the virus.

https://www.bbc.com/news/health-59178291

Edited by vememah
Link to comment

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...